These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 17283264

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W, Forder P, Simes J, Hunt D, Tonkin A, LIPID Investigators.
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [Abstract] [Full Text] [Related]

  • 4. A prospective study of pravastatin in the elderly at risk: new hope for older persons.
    Shepherd J.
    Am J Geriatr Cardiol; 2004 Apr; 13(3 Suppl 1):17-24. PubMed ID: 15133425
    [Abstract] [Full Text] [Related]

  • 5. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E, PROVE IT-TIMI 22 Investigators.
    J Am Coll Cardiol; 2005 Oct 18; 46(8):1417-24. PubMed ID: 16226164
    [Abstract] [Full Text] [Related]

  • 6. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
    van der Harst P, Asselbergs FW, Hillege HL, Bakker SJ, Voors AA, van Veldhuisen DJ, van Gilst WH, PREVEND-IT Investigators.
    Am J Cardiol; 2007 Nov 15; 100(10):1548-51. PubMed ID: 17996517
    [Abstract] [Full Text] [Related]

  • 7. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER Study Group.
    Circulation; 2005 Nov 15; 112(20):3058-65. PubMed ID: 16275871
    [Abstract] [Full Text] [Related]

  • 8. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.
    Arterioscler Thromb Vasc Biol; 2009 Mar 15; 29(3):424-30. PubMed ID: 19122170
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. C-reactive protein, bezafibrate, and recurrent coronary events in patients with chronic coronary heart disease.
    Haim M, Benderly M, Tanne D, Matas Z, Boyko V, Fisman EZ, Tenenbaum A, Zimmlichman R, Battler A, Goldbourt U, Behar S.
    Am Heart J; 2007 Dec 15; 154(6):1095-101. PubMed ID: 18035081
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E, PEACE Investigators.
    Circulation; 2007 Mar 27; 115(12):1528-36. PubMed ID: 17372173
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study.
    van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC.
    Arch Intern Med; 2003 Jun 09; 163(11):1323-8. PubMed ID: 12796068
    [Abstract] [Full Text] [Related]

  • 19. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
    Mora S, Rifai N, Buring JE, Ridker PM.
    Circulation; 2006 Aug 01; 114(5):381-7. PubMed ID: 16864722
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.